(via TheNewswire)

Not for distribution to United States Newswire Services or for dissemination in the United States

Vancouver, British Columbia, December 29, 2025 – TheNewswire - PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA) is pleased to announce a private placement offering (the " Offering ") of up to 4,000,000 units of the Company (the “ Units ”) at a price of $0.50 per Unit for gross proceeds and settlement of outstanding indebtedness of up to $2,000,000 (the “ Offering ”).

Each Unit will consist of one (1) Class A Common share in the capital of the Company (each a " Common Share ") and one (1) share purchase warrant (each a “ Warrant ”), with each Warrant being exercisable for one (1) additional Common Share (a " Warrant Share ") at a price of $0.75 per Warrant Share for a period of two (2) years from the date of issuance, subject acceleration.

It is anticipated that the net proceeds of the Offering will be utilized for general working capital purposes and to settle outstanding indebtedness of the Company, including indebtedness owed to certain directors and officers of the Company.

A regulatory hold period of four month plus one day will apply to all securities issued in connection with the Offering. Pursuant to the policies of the CSE, the Offering will close no earlier than five (5) business days from the date of this announcement.

Certain directors and officers of the Company (the “Insiders”) are expected to participate in the Offering, and any such participation would be considered a "related party transaction" as defined under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company expects to be exempt from the requirement to obtain a formal valuation and minority shareholder approval in connection with the Insiders’ participation in the Offering in reliance of Sections 5.5(a) and 5.7(a) of MI 61-101, respectively, on the basis that the Insiders’ participation in the Offering is not expected to exceed 25% of the fair market value of the Company's market capitalization.

This news release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act ") or any applicable state securities laws.  Such securities may not be offered or sold within the United States except pursuant to an effective registration statement under the U.S. Securities Act and the securities laws of any applicable state in the United States or pursuant to an available exemption from the registration requirements thereof.

About PanGenomic Health Inc.

PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The Company’s initial focus is to support mental health. Registered as a British Columbia benefit company, PanGenomic Health's mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.

For more information, please contact:

Fairfax Partners Inc.

Daniel Southan-Dwyer, President

+1 604 305 5369

fair@fairfax.partners

This news release includes certain statements that may be deemed “forward-looking statements”, including statements respecting the services to be provided by PanGenomic Health and the consideration to be paid to PanGenomic Health. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward looking statements. Although PanGenomic Health believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because PanGenomic can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. In particular, there is no assuance that the Company will be able to complete the Offering on the terms described above or at all, or that the Company will be able to sell of the securities being offered under the Offering.  These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in PanGenomic Health’s disclosure documents which can be found under PanGenomic Health’s profile on www.sedarplus.ca.

Copyright (c) 2025 TheNewswire - All rights reserved.